ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that a.macht contributed 10 entries already.
3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO) with locations in Pamplona (Spain) and Turku (Finland), has been awarded the prestigious CDMO Leadership Award 2025 in the “Cell & Gene Therapy International” category. This award recognizes the excellence of the services that 3PBIOVIAN provides to the Advanced Therapies industry, solidifying its position as a leader in the international sector.
The 15th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on 176 colored pages, the guide features a report about sustainability and the biologisation of industrial production. Readers will discover many success stories and current trends in the European biotech industry.
ARTES offers a brand-new business area making the hearts of all R&D staff beat faster. We have a whole range of first-class antigens, enzymes and functional proteins just waiting to be used in new, exciting projects.
Download Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.
Austria has once again come a little closer to its goal of achieving the highest research and development rate (R&D rate) in the EU. Two thirds of R&D investments are made by industry, of which around 16% are made by foreign companies. Two current examples of investments in Austria from the life sciences sector are Novartis and Ligand Pharmaceuticals.
Sino Biological, a leading recombinant protein production company, is pleased to announce an expansion of its strategic partnership with BioGeometry, a pioneer in digital biology. This collaboration brings together Sino Biological’s advanced protein expression and wet-lab capabilities with BioGeometry’s generative AI protein design and optimization platform. The two companies aim to enhance their joint offerings and explore high-value market opportunities globally.
Antibody-drug conjugates (ADCs) are a new class of biotherapeutics, consisting of acytotoxic payload covalently bound to an antibody by a linker. Evaluating the pharmacokinetics (PK) properties of ADCs in preclinical and clinical studies is essential for their strategic design and successful development.
The subject of impact measurement is of crucial importance for cluster organizations as they continuously aim to enhance their support to their ecosystems with ever more innovative and efficient services. Therefore, the INNAXE’s consortium has recently developed a “Toolbox for Cluster Organisations” allowing them to easily benchmark their regions and monitor the impact of their activities towards their stakeholders.
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors. Furthermore, using them together with a powerful bioprocess controller like the BioFlo® 320 enables precise cell culture parameter control and seamless process transition to up to 40 L of working volume.
Continuing geopolitical uncertainty has perpetuated volatility in global markets, exacerbated by higher inflation and interest rates. The impact has left the biotech market in a limbo as investors eschew riskier investments, but there are signs of a potential recovery ahead.